Insights On Partnering

  1. Advancing From Single Country Phase 1 Success To Multinational Phase 1/2 Trial 1/3/2024

    Explore how this partnership aims to contribute to the success of the trial by leveraging global resources and streamlining processes for efficient and timely results.

  2. Navigating The Future Of Clinical Trials: Expert Insights For 2025 2/26/2025

    The biopharmaceutical industry is undergoing transformative changes to develop more dynamic and efficient frameworks that prioritize patient outcomes in 2025.

  3. A Turnkey Solution For Clinical Trials In Australia 6/16/2025

    This presentation is centered on Australia's unique value proposition in the global research landscape, emphasizing its ability to deliver high-quality trials with speed and efficiency.

  4. Dermatology Drug Development: Key Takeaways From AAD 2025 3/24/2025

    The 2025 American Academy of Dermatology (AAD) Annual Meeting underscored pivotal advancements in dermatology drug development, highlighting the essential role of innovative dermatology CROs.

  5. TPDs: Developing The Next Generation Of Oral Therapeutics 10/20/2025

    Targeted Protein Degraders are a revolutionary drug class with challenges in bioavailability and formulation complexity. Strategic CDMO partnerships are key to successful, scalable development.

  6. Patient-Focused Strategies For Long-Term Follow-Up In Gene Therapies 7/2/2024

    As the landscape evolves, sponsors must adopt innovative, patient-centered approaches and technologies to effectively conduct LTFU studies, minimizing the burden on patients and research sites.

  7. Travel And Payment Services: A Patient's Journey 12/5/2025

    Streamline patient travel and payments in your clinical trials by implementing centralized, high-quality concierge services that reduce burdens, improve satisfaction, and boost study performance.

  8. The Real Power Of Digital Payments In Clinical Trials 10/8/2025

    Digital payments streamline clinical trials by reducing site burden, improving patient experience, eliminating manual delays, and delivering cleaner data across global studies.

  9. Quotient Sciences Capacity Update July 2025 7/29/2025

    Explore how expedited review pathways can be strategically used to accelerate development while mitigating CMC risks.

  10. Optimizing Chronic Cough Phase 3 Trials With Point-Of-Need Eye Assessments 1/15/2025

    Collaboration was key for Company W to overcome challenges with an FDA-mandated ocular substudy, including limited resources for ocular assessments and logistical difficulties